Get to know our clinical trials

Clinical trial with belantamab mafodotin in combination with Kd for the treatment of patients with relapsed multiple myeloma refractory to lenalidomide.

THE MAIN SPECIFIC OBJECTIVE IS TO INVESTIGATE WHETHER TREATMENT WITH BELANTAMAB MAFODOTIN CARFILZOMIB AND DEXAMETHASONE (KD) IS TOLERABLE AND SAFE AND, SECONDLY, TO DETERMINE THE EFFICACY OF THIS NEW DRUG COMBINATION IN TERMS OF DISEASE-FREE SURVIVAL.

Status
In recruitment

Technical Summary

  • PHASE I/II, OPEN-LABEL, MULTICENTER STUDY OF BELANTAMAB MAFODOTIN IN COMBINATION WITH KD FOR THE TREATMENT OF PATIENTS WITH RELAPSED MULTIPLE MYELOMA REFRACTORY TO LENALIDOMIDE. IMMUNOTHERAPY.
  • Code EudraCT: 2021-002125-15
  • Protocol number: GEM-BELMA
  • Promoter: Fundación Pethema
  • Link to Clinical Trials

* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.

More information about this clinical trial

Information offered by the Spanish Registry of Clinical Studies

  • Summary
  • Information
  • Calendar
  • Headquarters
  • Drugs

Do you want to participate in this trial?

Request an appointment for our specialists to assess whether you qualify for this clinical trial


Do you prefer to send us your reports?

If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.